Renaissance Technologies’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-500,605
| Closed | -$2.92M | – | 4541 |
|
|
2022
Q4 | $2.92M | Sell |
500,605
-142,000
| -22% | -$747K | ﹤0.01% | 1839 |
|
|
2022
Q3 | $4.3M | Sell |
642,605
-285,579
| -31% | -$1.73M | 0.01% | 1528 |
|
|
2022
Q2 | $3.91M | Buy |
928,184
+501,879
| +118% | +$1.99M | ﹤0.01% | 1740 |
|
|
2022
Q1 | $1.44M | Sell |
426,305
-149,500
| -26% | -$474K | ﹤0.01% | 2474 |
|
|
2021
Q4 | $1.81M | Sell |
575,805
-171,595
| -23% | -$571K | ﹤0.01% | 2219 |
|
|
2021
Q3 | $2.44M | Sell |
747,400
-245,600
| -25% | -$861K | ﹤0.01% | 1942 |
|
|
2021
Q2 | $4.19M | Buy |
993,000
+69,776
| +8% | +$295K | 0.01% | 1739 |
|
|
2021
Q1 | $4.61M | Buy |
923,224
+347,124
| +60% | +$2.81M | 0.01% | 1697 |
|
|
2020
Q4 | $7.28M | Sell |
576,100
-50,600
| -8% | -$577K | 0.01% | 1364 |
|
|
2020
Q3 | $6.15M | Sell |
626,700
-17,300
| -3% | -$170K | 0.01% | 1455 |
|
|
2020
Q2 | $6.41M | Buy |
644,000
+29,000
| +5% | +$278K | 0.01% | 1482 |
|
|
2020
Q1 | $5.44M | Sell |
615,000
-19,400
| -3% | -$191K | 0.01% | 1511 |
|
|
2019
Q4 | $5.85M | Buy |
634,400
+16,610
| +3% | +$118K | ﹤0.01% | 1753 |
|
|
2019
Q3 | $3.63M | Buy |
617,790
+1,790
| +0.3% | +$19K | ﹤0.01% | 1968 |
|
|
2019
Q2 | $7.39M | Sell |
616,000
-87,600
| -12% | -$942K | 0.01% | 1595 |
|
|
2019
Q1 | $8.49M | Buy |
703,600
+15,100
| +2% | +$223K | 0.01% | 1476 |
|
|
2018
Q4 | $8.64M | Sell |
688,500
-41,900
| -6% | -$578K | 0.01% | 1393 |
|
|
2018
Q3 | $10.8M | Buy |
730,400
+124,000
| +20% | +$1.95M | 0.01% | 1305 |
|
|
2018
Q2 | $10.2M | Buy |
606,400
+112,200
| +23% | +$2.18M | 0.01% | 1329 |
|
|
2018
Q1 | $11.3M | Buy |
494,200
+136,000
| +38% | +$3.02M | 0.01% | 1283 |
|
|
2017
Q4 | $9.27M | Sell |
358,200
-21,700
| -6% | -$437K | 0.01% | 1437 |
|
|
2017
Q3 | $5.6M | Sell |
379,900
-1,200
| -0.3% | -$17.4K | 0.01% | 1703 |
|
|
2017
Q2 | $5.32M | Buy |
381,100
+16,300
| +4% | +$240K | 0.01% | 1667 |
|
|
2017
Q1 | $6.22M | Sell |
364,800
-71,000
| -16% | -$852K | 0.01% | 1537 |
|
|
2016
Q4 | $4.48M | Buy |
435,800
+112,396
| +35% | +$1.03M | 0.01% | 1730 |
|
|
2016
Q3 | $3.27M | Buy |
323,404
+162,104
| +100% | +$1.77M | 0.01% | 1891 |
|
|
2016
Q2 | $1.81M | Sell |
161,300
-7,900
| -5% | -$101K | ﹤0.01% | 2245 |
|
|
2016
Q1 | $2.31M | Sell |
169,200
-19,689
| -10% | -$283K | ﹤0.01% | 2134 |
|
|
2015
Q4 | $3.58M | Buy |
+188,889
| New | +$4.1M | 0.01% | 1714 |
|
|
2015
Q2 | – | Sell |
-29,900
| Closed | -$453K | – | 3438 |
|
|
2015
Q1 | $453K | Buy |
+29,900
| New | +$417K | ﹤0.01% | 2631 |
|
Renaissance Technologies's CNCE Position: Q1 2023 in Review
Renaissance Technologies sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 500,605 shares — an estimated $2.92M sold.
Renaissance Technologies first reported a position in CNCE in Q1 2015 and held it in 30 quarters. The position peaked at $11.3M in Q1 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Renaissance Technologies reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Renaissance Technologies sold 500,605 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $2.92M.
- Renaissance Technologies first reported a position in Concert Pharmaceuticals, Inc. in Q1 2015 and held it in 30 quarters.
- Renaissance Technologies's Concert Pharmaceuticals, Inc. position peaked at $11.3M in Q1 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.